MS Ireland is conducting a short, anonymous survey about disease modifying therapies (DMTs).

The DMTs that are currently available in Ireland are:

Aubagio (Terflunomide)
Avonex (Beta Interferon 1a)
Betaferon (Beta Interferon 1b)
Copaxone (Glatiramer Acetate)
Gilenya (Fingolimod)
Lemtrada (Alemtuzumab)
Plegridy (Peginterferon beta 1a)
Rebif (Beta Interferon 1a)
Tecfidera (Dimethyl Fumarate)
Tysabri (Natalizumab)

This survey will take approximately 10-15 minutes to complete. The purpose of the survey is to help us to understand what is important to people with MS regarding their treatment options. Our recent My MS My Needs survey found that almost 20% of people with MS felt they had not received enough information from healthcare professionals about available drugs.

The results of this survey will help guide us as to what information materials people would like access to, to help them make decisions about treatments and help them manage their medications. Data and information from the survey may also be used in future Patient Group Submissions to the National Centre for Pharmaco-economics (NCPE), to help with the process of trying to make new medications for MS available in Ireland.

If you have any questions about the survey, please contact Harriet Doig – harrietd@ms-society.ie

T